RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 9 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Pathologically confirmed CLL/SLL according to the 2018 revised IWCLL NCI-WG guidelines, subject with measurable lesions or splenomegaly due to CLL.

    Inclusion criterion 2

  3. Prior history of allogeneic hematopoietic stem cell transplantation, adoptive cell immunotherapy or autologous hematopoietic stem cell transplantation within 24 months.

    Exclusion criterion 1

    Received Bcl-2 inhibitor treatment.

    Exclusion criterion 3

    Pregnancy or lactation, or pregnancy is expected during the study period or within 3 months after the last administration of treatment.

    Exclusion criterion 5

  4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -2.

    Inclusion criterion 5

  5. Within 2 years before entering the study, the subject had a history of active malignant tumors other than CLL / SLL, except that:

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05147467, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

Subjects who meet each of the following inclusion criteria are eligible to participate in this study:

  • Age ≥18 years old.
  • Pathologically confirmed CLL/SLL according to the 2018 revised IWCLL NCI-WG guidelines, subject with measurable lesions or splenomegaly due to CLL.
  • Expected survival is at least 12 weeks.
  • Refractory, recurrent, or intolerant to BTK inhibitors and immunochemotherapy,or first-line treatment with BTK inhibitors fails and is not suitable for immunochemotherapy.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -2.
  • Ability to understand and willingness to sign a written informed consent form approved by EC committee (the consent form must be signed by the patient prior to any screening or study-specific procedures).
  • Willingness and ability to comply with study procedures and follow-up examination.

Exclusion Criteria:

Subjects who meet any of the following exclusion criteria are not to be enrolled in this study:

  • Prior history of allogeneic hematopoietic stem cell transplantation, adoptive cell immunotherapy or autologous hematopoietic stem cell transplantation within 24 months.
  • Failure to recover adequately, at the discretion of the investigator, from prior surgical procedures. Patients who have had major surgery within 28 days from study entry, and patients who have had minor surgery within 14 days of study entry.
  • Received Bcl-2 inhibitor treatment.
  • Invasive NHL transformation or central nervous system (CNS) involvement has occurred.
  • Pregnancy or lactation, or pregnancy is expected during the study period or within 3 months after the last administration of treatment.
  • Within 2 years before entering the study, the subject had a history of active malignant tumors other than CLL / SLL, except that:
  • Fully treated cervical carcinoma in situ;
  • Completely resected basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
  • Confinement and resection of previously cured malignancies (or other treatment).
  • Any other condition or circumstance that would, at the discretion of the investigator, make the patient unsuitable for participation in the study.

Quoted from ClinicalTrials.gov, NCT05147467, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05147467, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05147467